Quest Diagnostics

DGX · NYSE

$237.12+$2.21 (+0.94%)TodayMarket closed · Oct 20, 7:34 PM ET

Prev close $234.91

DGX analyst rating

HoldConsensus of 12 analysts over the last 12 months. 42% rate it a buy.

Strong buy0
Buy5
Hold7
Underperform0
Sell0

12-month price target · 18 analysts

Average $250.60 (+5.7% upside)

Low: $210.42
Now: $237.12
High: $278.25

Upgrades and downgrades

The latest rating actions, newest first

DGX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 7, 2026	Maintains	Overweight	$250.00 → $260.00	54%
Truist Securities	Sep 21, 2026	Maintains	Hold	$250.00 → $260.00	67%
UBS	Sep 8, 2026	Maintains	Neutral	$232.00 → $245.00	70%
JP Morgan	Jul 28, 2026	Maintains	Neutral	$220.00 → $250.00	54%
UBS	Jul 24, 2026	Maintains	Neutral	$220.00 → $232.00	70%
Mizuho	Jul 24, 2026	Maintains	Outperform	$235.00 → $260.00	69%
Truist Securities	Jul 24, 2026	Maintains	Hold	$225.00 → $250.00	67%
Barclays	Jul 24, 2026	Maintains	Overweight	$230.00 → $250.00	54%
Baird	Jul 24, 2026	Maintains	Neutral	$236.00 → $255.00	64%
Baird	Jul 13, 2026	Maintains	Neutral	$232.00 → $236.00	64%

The case for and against

Updated Jul 28, 2026

Bull case

Quest Diagnostics is poised for strong growth in the upcoming years as their core trends, including revenue, adjusted EPS, and AOI, continue to surpass expectations. The company's recent partnerships, such as the FMS and Corewell deals, are expected to drive significant revenue growth in 2026. Additionally, the company's strong performance in the physician channel, with high single-digit growth and expanded health plan access, provides potential for continued volume growth. Despite potential headwinds, such as weather and increased investment, DGX maintains a strong financial position with solid cash flow and a healthy balance sheet.

Bear case

Quest Diagnostics is poised for growth with strong first quarter results, beating both top and bottom-line estimates and increasing guidance for FY26. With strong organic volumes and growth in Advanced Diagnostics, as well as investments in AI and automation, the company is well-positioned for future success. Despite solid cash flow and a strong M&A/partnership pipeline, the negative outlook remains due to potential challenges in the healthcare industry such as potential regulation changes and competition from emerging companies.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.